MEN2501 treatment for platinum-resistant ovarian cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This first-in-human, open-label Phase 1 study uses dose-escalation and dose-optimization to find a safe and tolerable dose of MEN2501 as a single agent for adults with platinum-resistant ovarian, primary peritoneal, or fallopian tube cancer. The trial will measure safety, tolerability, pharmacokinetics, pharmacodynamics, and any signs of antitumor activity. Participants will receive escalating doses at the study site with regular safety labs, imaging, and PK/PD sampling to guide dose decisions. Cohorts may expand at recommended doses to further characterize preliminary activity and side effects.

Why it matters

Who can join: the full rules

Key Inclusion Criteria:

* Participants must have a histopathologically confirmed diagnosis of high-grade serous ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.

Key Exclusion Criteria:

* Participants with primary platinum-refractory disease.

Note: Other protocol-defined inclusion/exclusion criteria may apply.

Where it's running

• Highlands Oncology Group
  Springdale, Arkansas, United States Recruiting
• Yale University
  New Haven, Connecticut, United States Recruiting
• Florida Cancer Specialists & Research Institute
  Sarasota, Florida, United States Recruiting
• Massachusetts General Hospital
  Boston, Massachusetts, United States Recruiting
• Karmanos Cancer Institute
  Detroit, Michigan, United States Recruiting
• Mayo Clinic
  Rochester, Minnesota, United States Recruiting

Study contacts

• Study coordinator: Stemline Trials
• Email: cwilliams@menarinistemline.com; MEN2501_StudyTeam@menarinistemline.com
• Phone: 1-877-332-7961

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• SYS6043 plus standard chemo vs standard chemo in platinum-resistant ovarian, primary peritoneal, or fallopian tube cancer

  This study tests SYS6043 against the doctor’s choice chemotherapy in adults with platinum-resistant ovarian, primary peritoneal, or fallopian tube cancer to see which treatment works better.

  Recruiting Phase 3 CSPC Megalith Biopharmaceutical Co.,Ltd. · Beijing, Beijing Municipality · NCT07708753

• OPB-201 therapy for recurrent endometrial and platinum-resistant ovarian cancer

  A one-time treatment with a patient’s own T cells engineered to target PRAME is being tested to see if it is safe and what dose works best for adults with recurrent endometrial cancer or platinum-resistant ovarian cancer.

  Recruiting at 5 sites Phase 1 Outpace Bio, Inc. · San Francisco, California and 4 other locations · NCT07664735

• Rina-S extension study in platinum-resistant ovarian cancer in China

  This study tests whether Rina-S works as well as standard chemotherapy options for people with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer in China.

  Recruiting at 17 sites Phase 3 Genmab · Changchun and 16 other locations · NCT07604766

• GB-5267 for platinum-resistant ovarian, peritoneal, or fallopian tube cancer

  This early-phase trial test GB-5267 in adults with platinum-resistant ovarian cancer to see if it is safe and can help shrink tumors.

  Recruiting Phase 1 Roswell Park Cancer Institute · Buffalo, New York · NCT07489287

• MUC16-targeted antibody-drug HWK-016 for advanced ovarian and endometrial cancer

  This will test HWK-016, an antibody-drug that targets MUC16, in adults with advanced or metastatic ovarian or endometrial cancer, including platinum-resistant ovarian cancer.

  Recruiting at 9 sites Phase 1 Whitehawk Therapeutics, Inc. · Little Rock, Arkansas and 11 other locations · NCT07470853

• HWK-007, a PTK7-targeted antibody‑drug conjugate for advanced PTK7-positive ovarian, endometrial, and certain non‑squamous lung cancers

  This study will try HWK-007, a PTK7-targeted antibody‑drug conjugate given every three weeks, to see if it can shrink or control advanced PTK7-positive ovarian, endometrial, or non-squamous EGFR wild-type lung cancers.

  Recruiting at 10 sites Phase 1 Whitehawk Therapeutics, Inc. · Little Rock, Arkansas and 11 other locations · NCT07444814

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.